Treatment of oral mucosal manifestations of chronic graft-versus-host disease: dexamethasone vs. budesonide

Yehuda Zadik,Sharon Elad,Anat Shapira,Michael Y Shapira
DOI: https://doi.org/10.1080/14656566.2017.1282464
2017-01-25
Expert Opinion on Pharmacotherapy
Abstract:INTRODUCTION: The oral mucosa is commonly involved in chronic graft-versus-host disease (cGVHD). Oral mucosal cGVHD markedly affect individual's daily function and wellbeing. In some cases, it might become a life threating complication. Areas covered: This article describes the rationale for treatment, method of topical application in the oral cavity, evidence supporting the topical administration of dexamethasone and budesonide for oral cGVHD, and their adverse effects. Expert opinion: Evidence supports the use of topical dexamethasone and budesonide for treatment of oral cGVHD. Topical corticosteroid choice for oral cGVHD, takes into consideration the potency, bioavailability, preferred concentration, and possible adverse effects. Budesonide's pharmacological characteristics mark it as a preferable topical agent for oral cGVHD.
pharmacology & pharmacy
What problem does this paper attempt to address?